InnoMed Technologies' Nasal-Aire II Critical Care Receives FDA Clearance

BOCA RATON, Fla.--(BUSINESS WIRE)--January 27, 2004 InnoMed Technologies announced today that its Nasal Aire II Critical Care device has received clearance from the U.S. Food and Drug Administration (FDA). The Nasal Aire II Critical Care, a disposable unit introduced in December 2003 for use in hospital and critical care environments, is based on the highly successful Nasal-Aire CPAP interface.

'The demand for a disposable critical care interface has been tremendous and the FDA clearance for this product gives us the green light to make this product available to hospitals and critical care settings throughout the U.S.,' said Patrick Karem, C.E.O. of InnoMed Technologies. 'We expect to garner a large portion of the critical care CPAP and non-invasive ventilation market this year.'

In addition to introducing the Nasal Aire II Critical Care in 2003, InnoMed Technologies unveiled its The Nasal Aire II for Obstructive Sleep Apnea (OSA), an upgrade of the original Nasal-Aire CPAP device which hit the market in 2002. A new market research report by San Francisco-based First Albany determined that in slightly more than one year, InnoMed has cornered 10 percent of the U.S. interface market.

InnoMed designs, manufactures and markets the innovative Nasal-Aire, Nasal-Aire II and the Nasal-Aire II Critical Care. Independent clinical trials have shown that when patients are given a choice between using the Nasal-Aire or the three leading competitive masks, manufactured by Resmed, Inc. (NYSE:RMD), Respironics (Nasdaq:RESP), and Mallinckrodt, 98% of the time Nasal-Aire was chosen.

InnoMed Technologies, Inc., is a research-oriented, privately held, 21st Century medical technologies company. The company is poised to bring new and more effective medical products and devices to the public through a medical development and engineering team, as well as acquisitions of other medical related companies. InnoMed holds several patents and has several patents pending. More information regarding InnoMed Technologies is available at http://www.innomedinc.com.

A Private Securities Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain information included in this press release (as well as information included in written statements to be made) contain statements that are forward-looking, such as those relating to consummation of the transaction, anticipated future revenue of the Company, and success of current public offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ materially from those expressed in any forward looking statements.